Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

#3932

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Aim(s): (Included in Methods)

Materials and methods: Either sequential lobar or whole liver treatment with yttrium-90 (Y-90) glass microspheres was conducted. Primary outcomes: 1. Objective response rate (ORR) in the treated liver volume (RECIST 1.1, mRECIST criteria) 2. Incidence and severity of adverse events (AEs) at 6months. Secondary outcomes: 1. liver specific progress free survival (LPFS), progression free survival (PFS), overall survival (OS), quality of life (QoL) using QLQ C-30 and GI.NET21.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,